Ivermectin — Ivermectin 12mg, 90 Tablets

Ivermectin — 90 Tablets

This product listing features a complete bottle containing 90 tablets of Ivermectin. This standardized volume is optimized to provide a highly precise and consistent supply for continuous evaluation or multi-cycle research within advanced metabolic, cellular longevity, and antiparasitic frameworks.

General Pharmaceutical & Chemical Information

• Active Ingredient: Ivermectin
• Dosage: 12 mg of Ivermectin per tablet
• Package Size: 1 Bottle (90 tablets)
• CAS Number: 70288-86-7
• Molecular Formula: C48H74O14 (for the major component, Avermectin B1a)
• Form: Oral tablets
• Application: For Research Applications Only.

Primary Focus: Oncology Prevention and Adjuvant Therapy

While traditionally classified as an antiparasitic, Ivermectin is highly utilized off-label in translational research as a potent, multi-targeted anti-tumor agent. A growing body of preclinical data and early-phase clinical trials evaluate its efficacy in oncology through several distinct pathways:

• Selective Cytotoxicity via Chloride Ionophore Activity: Ivermectin acts as a chloride ionophore. Because cancer cells rely heavily on chloride channels for volume regulation and survival, the increased intracellular chloride influx selectively disrupts their metabolic balance, inducing oxidative damage and apoptosis while sparing healthy cells.
• Mitochondrial Complex I Inhibition: It has been shown to directly inhibit Mitochondrial Complex I, severely limiting ATP production within energy-demanding cancer cells. This metabolic depletion triggers acute oxidative stress, forcing apoptosis.
• Induction of Immunogenic Cell Death (ICD): Ivermectin helps convert immunologically “cold” tumors into “hot” tumors. By promoting the release of key danger-associated molecular patterns (DAMPs) like ATP and HMGB1, it recruits and activates T-cells, priming the immune system to detect and attack tumor cells.
• Targeting Cancer Stem Cells (CSCs): It selectively targets cancer stem cells, the highly resilient subpopulation responsible for chemotherapy resistance, tumor recurrence, and metastasis.
• Inhibition of Key Oncogenic Pathways: Ivermectin blocks critical signaling cascades involved in tumor growth and cell survival, including the Wnt/β-catenin, PAK1/Akt/mTOR, and STAT3 pathways.

Anti-Aging & Longevity Properties (Geroprotection)

Beyond oncology, Ivermectin is evaluated in anti-aging science for its systemic cellular maintenance mechanisms:

• Stimulation of Autophagy: By inhibiting the PAK1/Akt/mTOR pathway, Ivermectin upregulates cytostatic autophagy—the essential quality-control mechanism that clears out damaged proteins, dysfunctional organelles, and cellular debris.
• Mitigation of Chronic Inflammation (Inflammaging): It demonstrates anti-inflammatory properties by suppressing key pro-inflammatory cytokine pathways (such as NF-κB), reducing the systemic low-grade inflammation that accelerates tissue aging.

Administration, Storage & Strict Disclaimer

In advanced oncology and longevity protocols, Ivermectin is typically administered in intermittent, pulse-dosing cycles rather than continuous daily use to maximize cellular sensitivity.

• Storage: Keep container tightly closed. Store in a cool, dry environment, protected from heat, moisture, and direct sunlight. Do not freeze.

Strict Regulatory Disclaimer: This product is intended solely for laboratory research, in vitro evaluation, and analytical purposes. We do not provide medical advice, recommend specific protocols, or guarantee any therapeutic results. Nothing stated herein should be construed as a medical recommendation or a guarantee of efficacy in treating, curing, or preventing any disease, including cancer. Any practical application of this compound must be strictly validated by independent research and overseen by a qualified professional.